Our MOTS-c pen holds 32 mg in 3 ml as a pre-loaded multi-dose pen. MOTS-c is one of the more genuinely interesting molecules in this catalogue on mechanistic grounds — it is encoded in mitochondrial rather than nuclear DNA — and one of the least developed clinically. Both facts belong on the same page. Batch certificates are published at /coa.
The foundational work is well cited and entirely preclinical. No human efficacy trial has been published. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015;21(3):443–454. PMID 25738459; MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. PMC5116416; Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. PMC9854231; The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? PMID 26289118
What “mitochondrially encoded” means
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA. Almost every peptide of research interest is encoded in nuclear DNA; MOTS-c is not.
That is genuinely unusual and it is the reason the 2015 paper attracted the attention it did. It suggested mitochondria act as a signalling origin rather than only as an energy-producing organelle — a conceptual shift rather than an incremental finding.
It also explains why MOTS-c gets filed alongside NAD+ under headings like “mitochondrial peptides” despite the two being completely different kinds of molecule. NAD+ is a coenzyme, not a peptide. That confusion is addressed at mitochondrial peptides.
The reported mechanism
The 2015 work identified skeletal muscle as the primary target organ. The described cellular route is inhibition of the folate cycle and the de novo purine biosynthesis tethered to it, producing a large increase in endogenous AICAR — reported as greater than twenty-fold — which in turn activates AMPK signalling.
AMPK is a central metabolic sensor, which is why activating it is the mechanistic hook for essentially every metabolic claim made about this compound.
What was actually observed, and in what
In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance, and prevented diet-induced obesity — the finding behind the weight-loss listing. Later work explored relationships between exercise, dietary intervention, ageing and MOTS-c production, with skeletal muscle as the main target of the circulating peptide and evidence pointing to fat cells as a further one.
Every one of those findings is from cell culture or rodent models. No published human efficacy trial exists. There is no established human dose, no human safety dataset, and no clinical outcome data of any kind.
The gap between “prevented diet-induced obesity in mice” and any statement about a person is the entire distance between preclinical and clinical evidence, and no amount of mechanistic elegance closes it.
Where the search results go, and why
Queries about MOTS-c are dominated by PubMed Central, anti-doping bodies and reference sources rather than by merchants. That reflects the compound’s actual position: it is an active research subject with a real literature and no commercial clinical development behind it.
We mention this because it shapes what an honest page can offer. On a compound this early, the useful contribution is an accurate statement of what has been shown and in what species — not a longer version of the same mechanistic summary.
What this pen is
A research pen containing MOTS-c, third-party tested per batch for identity, purity and sterility, with the certificate for the specific lot reachable from the QR code. MOTS-c holds no marketing authorisation anywhere.
What we can evidence is what is in the pen. What we cannot evidence — and will not imply — is an outcome in a human being, because nobody has published one — under this heading or under peptides for longevity.
Related: what is MOTS-c?, MOTS-c vs NAD+, peptides for energy, the recovery goal page.
